Monograph
A10BJ03 - Lixisenatide |
Propably not porphyrinogenic |
PNP |
Important Information
Very common adverse reactions of lixisenatide that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Side effects
Very common adverse reactions of lixisenatide that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Lixisenatide is not metabolized by the cytochrome P450 system, and is not an inducer or an inhibitor of these enzymes.
Chemical description
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Therapeutic characteristics
Lixisenatide is a glucagon-like peptide-1 receptor agonist used in diabetes type 2 in combination with other orally administered anti-diabetics. It is administered subcutaneously.
Metabolism and pharmacokinetics
Lixisenatide is a peptide and is therefore not hepatically metabolized but rather eliminated by glomerular filtration or proteolytic degradation. Interactions involving cytochrome P450 isoenzymes are not expected (Hurren 2012). In in vitro studies, lixisenatide did not affect the activity of cytochrome P450 isozymes or human transporters tested (SPC).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Occurrence of nausea, vomiting, and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K, Kahle M et al. Diabetes Obes Metab. 2016 Nov 9. doi: 10.1111/dom.12824. |
27860132 |
| 2. | Drug-drug interactions with glucagon-like peptide-1 receptor agonists.
Hurren KM, Pinelli NR. Ann Pharmacother. 2012 May; 46(5):710-7. Epub 2012 Apr 17. |
22510669 |
| * | Summary of Product Characteristics | |
| 3. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Lyxumia.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024